Brief Report

Don't forget about syphilis: sexually transmitted diseases during COVID-19 pandemic

Andrea Di Buduo,1 Laura Atzori,1 Luca Pilloni,2 Stefania Perla,1 Franco Rongioletti,1 Caterina Ferrelli1

1Unit of Dermatology; 2Unit of Pathology, Department Medical Sciences and Public Health, University of Cagliari, Italy

Abstract

A great heterogeneity of skin manifestations has been increasingly associated with SARS-CoV2 infection, and especially exanthematous eruptions are considered among early presenting signs in symptomatic patients. In this report, a 58-year-old patient presented with fever, generalized rash and systemic symptoms as urgent consultation to the Dermatology Clinic of Cagliari amidst the Italian outbreak in late March 2020. After a negative nasopharyngeal swab for SARS-CoV-2, secondary syphilis was confirmed by serological tests and skin biopsy, underlining that, even during a global pandemic, other common and important diseases should not be overlooked. The case also suggests thought on the ineffectiveness of distancing and social containment measures when dealing with sexually transmitted diseases.

Introduction

On 11th March 2020, the World Health Organization (WHO) declared coronavirus 2019 disease (COVID-19) a pandemic.1 In addition to the most common clinical features of COVID-19, which include fever, myalgia, cough, shortness of breath, ageusia, anosmia and conjunctival congestion,2 skin symptoms can occur in up to 20.4% of patients.3

A challenging aspect of such skin eruptions associated with COVID-19 is the great heterogeneity, that challenges a broad spectrum of differential diagnoses.4 As the dermatologic signs may precede the respiratory symptoms or manifest themselves in the absence of any pulmonary manifestations, it is important to consider COVID-19 infection in case of any exanthematous eruptions to minimize the risk of spreading by pauci-symptomatic individuals in an endemic area. On the contrary, fear should not deter us from recognizing common disorders.

Case Report

In late March 2020, amidst the COVID-19 outbreak, a 58-year-old Caucasian man affected by insulin-treated type 2 diabetes referred to the Dermatology Clinic under the suspicion of SARS-CoV-2 infection for a generalized, mildly pruritic exanthematous rash associated with systemic symptoms of 2-week duration. He had been treated by the general practitioner with paracetamol and systemic steroids with some improvement, followed by relapse of symptoms and worsening of the skin eruption. He denied recent travels to the high-prevalence areas for SARS-CoV-2 infection.

On physical examination, the patient presented with a widespread erythematous morbilliform rash, slightly papular and scaly at closer view on the trunk and radix of the limbs (Figures 1 and 2), more erythematous edematous on the face, with bilateral conjunctival erythema (Figure 2), associated with fever (37.9°C), cough, rhinitis, pharyngodynia, occipital headache, diffuse lymphadenopathy and symmetrical migratory arthritis. Isolated papules were present on the soles while palmar regions were spared. After inquiring the patient, he referred also a genital rash, which spontaneously resolved, two months earlier. Nasopharyngeal swab for SARS-CoV-2 was negative. The ophthalmologic consultation diagnosed a pan-uveitis.

Histopathology of a skin biopsy showed a mild interface dermatitis, with superficial and deep dermal perivascular and perianexial inflammatory infiltrate, whose multinucleated histiocytes formed several noncaseating granulomas in a background of lymphocytic infiltrate, rich in plasma cells (Figure 3). A positive Treponema pallidum hemagglutination (TPHA) test (>1:5120) as well as a rapid plasma reagin test (RPR 1: 64) confirmed the diagnosis of secondary syphilis. The patient was treated with penicillin G benzathine 2,400,000 UI intramuscularly weekly for 3 weeks with rapid improvement of systemic symptoms and complete resolution of the skin rash.

Significance for public health

Even during a pandemic, despite community containment and social distancing, sexually transmitted diseases persist, and syphilis should never be forgotten. As highlighted by present report, the potential impact on public health is substantial, considering that secondary syphilis is a highly contagious generalized bacteremic phase of the disease. Resurgence of syphilis is an ongoing unsolved problem for at least a decade, which takes a back seat to the current dramatic COVID-19 spreading. However, limitation to outpatients’ visits and hospital screening services due to the lockdown measures are likely to favor syphilis circulation, delay diagnosis and adequate treatment. Dermatologists are in the leading position to support the medical community in such difficult situations, keeping focused on good clinical practice to promptly recognize subtle but potentially severe diseases like syphilis.
The patient was tested negative for additional STD and at the trimestral follow up, RPR antibody titer had decreased (1:8), while TPHA test remained stable (1:5120).

Discussion

The reported prevalence of cutaneous signs associated with COVID-19 pandemic is variable, ranging from the 0.2% of a cohort of 1099 Chinese patients, to the 20.4% in a cross-sectional Italian study. Exanthematous eruptions are considered the most common, although less specific COVID-19 related skin manifestations, reported in about 47% of cases. The morphology is very polymorphic, and classification is limited by the subjectivity of the different reports’ description, going from widespread erythema to urticarial, varicella-like-vesicular, purpuric, maculopapular, morbilliform and papulo-squamous presentation. In the American registry, 22% of the patients with laboratory-confirmed COVID-19 infection presented with a morbilliform rash, while another 9% with a papulo-squamous eruption, occurring mostly on the trunk and associated with mild itching. It is therefore not surprising that the occurrence of a generalized morbilliform papular rash associated with cough and arthritis among the others, during the most critical moment of the outbreak led to consider first a COVID-19 related manifestation. Of course, a closer observation recognized that all skin and systemic symptoms in our patient were typical of secondary syphilis, but one must also consider that admitting a person potentially affected with COVID-19 to hospital triggers a series of containment measures, and careful assessment should be performed.

Moreover, social distancing and strict preventive measures during the lockdown are supposed to affect also the circulation of other infectious diseases, such as syphilis. A decrease in STI diagnoses, particularly of early syphilis have been reported in Italy during the period of lockdown. Our experience suggests not to let the guard down. Despite the global health emergency and the fear of non-recognizing COVID-19, other common diseases should not to be disregarded in everyday clinical practice. This is particularly true for a disease like secondary syphilis which can cause a wide range of symptoms, as the nickname of “great masquerader” points out, similar to actual COVID-19 manifestations.

Conclusion

Current pandemic is adsorbing most of the resources of our healthcare system, and specialty outpatients’ services, as well as Hospital Units not directly involved in critically ill COVID-19 patients’ risk to be overshadowed. A false sense of protection and social containment generated by lockdown measures can lead to underestimating sexually transmitted diseases circulation in the community. Especially syphilis diagnosis requires an expert eye, and a high level of suspicion, as it is characteristic of the dermatology on-field practice.
References

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91:157-60.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;82:1708-20.
3. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34:e212-3.
4. Galván Casas C, Catalá A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020;183:71-7.
5. Marzano AV, Cassano N, Genovese G, et al. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol 2020;183:431-42.
6. Gottlieb M, Long B. Dermatologic manifestations and complications of COVID-19 American J Emerg Med 2020:38.1715-21.
7. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol 2020;83:1118-29.
8. Liew IY, Mak TM, Cui L, et al. A case of reactive arthritis secondary to Coronavirus Disease 2019 infection. J Clin Rheumatol 2020;26:233.
9. Gisondi P, Piilerico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol 2020;34:1196-201.
10. Latini A, Magri F, Donà MG, et al. Is COVID-19 affecting the epidemiology of STIs? The experience of syphilis in Rome. Sex Transm Infect 2020. doi: 10.1136/sextrans-2020-054543
11. Sacchelli L, Viviani F, Orioni G, et al. Sexually transmitted infections during the COVID-19 outbreak: comparison of patients referring to the service of sexually transmitted diseases during the sanitary emergency with those referring during the common practice. J Eur Acad Dermatol Venereol 2020;34:e553-6.

Correspondence: Prof. Atzori Laura, Clinica Dermatologica, Via Ospedale 54, 09124 Cagliari, Italy.
Tel. +39.338.8526881- Fax: +39.070.51092303. E-mail: atzoril@unica.it

Key words: COVID-19; SARS-CoV-2; homeless population; screening; fragile populations.

Funding: None.

Conflicts of interest: The authors declare that they have no competing interests, and all authors confirm accuracy.

Contributions: All authors contributed equally to the manuscript concept and design, as well as to revision and approval of the final text. All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Ethics approval and consent to participate: No ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: The patient gave written consent to the publication of the images.

Received for publication: 21 November 2020. Accepted for publication: 3 December 2020.

©Copyright: the Author(s), 2020
Licensee PAGEPress, Italy
Journal of Public Health Research 2020;9:2040
doi:10.4081/jphr.2020.2040
This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).